Key Points
- Insider purchase: Dr Darrin Disley bought 5,000,000 shares of Roquefort Therapeutics on November 21 at GBX 170 per share, a transaction totalling £8,500,000.
- Financial snapshot: Roquefort is a very small-cap biotech (market cap £2.98M) trading around GBX 1.89 with a one-year range of GBX 1.08–5.50, reported quarterly EPS of GBX −0.33, and negative profitability metrics.
- Business focus: The company develops first-in-class oncology drugs and has expanded its pipeline through acquisitions of Lyramid Pty and Oncogeni Ltd (cell and RNA oncology assets, including Midkine-targeted programs).
Roquefort Therapeutics plc (LON:ROQ - Get Free Report) insider Dr Darrin Disley acquired 5,000,000 shares of the business's stock in a transaction dated Friday, November 21st. The shares were bought at an average price of GBX 170 per share, for a total transaction of £8,500,000.
Roquefort Therapeutics Price Performance
Roquefort Therapeutics stock opened at GBX 1.89 on Tuesday. Roquefort Therapeutics plc has a 1 year low of GBX 1.08 and a 1 year high of GBX 5.50. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79. The firm has a 50 day moving average price of GBX 1.93 and a 200 day moving average price of GBX 1.71. The company has a market cap of £2.98 million, a price-to-earnings ratio of -3.00 and a beta of 0.05.
Roquefort Therapeutics (LON:ROQ - Get Free Report) last posted its quarterly earnings results on Tuesday, September 30th. The company reported GBX (0.33) earnings per share for the quarter. Roquefort Therapeutics had a negative return on equity of 29.57% and a negative net margin of 57,057.07%.
About Roquefort Therapeutics
(
Get Free Report)
Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
